ABVC BioPharmaABVC
Market Cap: 9.03M
About: ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Employees: 19
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 0
159% more capital invested
Capital invested by funds: $129K [Q4 2023] → $333K (+$204K) [Q1 2024]
0.98% more ownership
Funds ownership: 1.43% [Q4 2023] → 2.41% (+0.98%) [Q1 2024]
0% more funds holding
Funds holding: 8 [Q4 2023] → 8 (+0) [Q1 2024]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for ABVC.